Minimally invasive endoscopic therapies for gastro-oesophageal reflux disease. Issue 3 (2nd February 2023)

• Record Type: Journal Article
• Authors: Aslam, Nasar; Telese, Andrea; Sehgal, Vinay; Sweis, Rami; Lovat, Laurence B; Haidry, Rehan
• Is Part Of: Frontline gastroenterology. Volume 14:Issue 3(2023)
• Page Start: 249
• Page End: 257
• Publication Date: 2023-02-02
• Subjects: anti-reflux therapy -- gastroesophageal reflux disease -- oesophageal reflux -- endoscopy -- diagnostic and therapeutic endoscopy; Gastroenterology -- Periodicals; 616.33005
• DOI: 10.1136/flgastro-2022-102343
• Languages: English
• ISSNs: 2041-4137

Abstract

Abstract : The prevalence of the gastro-oesophageal reflux disease (GORD) in the western world is increasing. Uncontrolled GORD can lead to harmful long-term sequela such as oesophagitis, stricture formation, Barrett's oesophagus and oesophageal adenocarcinoma. Moreover, GORD has been shown to negatively impact quality of life. The current treatment paradigm for GORD consists of lifestyle modification, pharmacological control of gastric acid secretion or antireflux surgery. In recent years, several minimally invasive antireflux endoscopic therapies (ARET) have been developed which may play a role in bridging the unmet therapeutic gap between the medical and surgical treatment options. To ensure optimal patient outcomes following ARET, considered patient selection is crucial, which requires a mechanistic understanding of individual ARET options. Here, we will discuss the differences between ARETs along with an overview of the current evidence base. We also outline future research priorities that will help refine the future role of ARET.